Celgene to provide oral presentations on beta-thalassemia.

Acceleron, Celgene to provide oral presentations on beta-thalassemia, myelodysplastic syndromes at EHA meeting Acceleron Pharma Inc http://propeciauk.org . , a scientific stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for tumor and rare diseases, reported that Acceleron today, Celgene and investigators in the sotatercept and ACE-536 phase 2 clinical trials will give three oral presentations of interim data from ongoing research in beta-thalassemia and myelodysplastic syndromes in addition to a poster display of nonclinical data in sickle cell disease at the 19th Annual Congress of the European Hematology Association in Milan, From June 12-15 Italy, 2014.

We are confident that this deal provides PiC the precise opportunity we need to expand and diversify our portfolio further to provide patients genuine choice across the spectral range of behavioral healthcare. Furthermore we have noticed that Acadia shares our lifestyle of compassionate care and believes, as we perform, that it is the building blocks of our past and potential success. UK Behavioral Wellness Market Opportunity The independent behavioral health market represents approximately 8 percent of the total behavioral health marketplace, or around $2 billion, and is continuing to grow at a 9.2 percent substance annual rate since 2004.